CLINICAL RESEARCH: BIOMARKER
Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population
Carolyn S.P. Lam, MBBS, MRCP*, ,
John C. Burnett, Jr, MD*,
Lisa Costello-Boerrigter, MD, PhD*,
Richard J. Rodeheffer, MD, FACC* and
Margaret M. Redfield, MD, FACC*,1,*
* Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Manuscript received July 10, 2006;
revised manuscript received October 31, 2006,
accepted November 2, 2006.
* Reprint requests and correspondence: Dr. Margaret M. Redfield, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905. (Email: redfield.margaret{at}mayo.edu).
Objectives: This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms circulate in the general population.
Background: Bioactive BNP1-32 and NT-proBNP1-76 are derived from a precursor molecule, proBNP1-108. Recent data suggest that aminodipeptidase-processed forms of BNP1-32 (BNP3-32) and of proBNP1-108 itself (proBNP3-108) may circulate and have additional diagnostic potential.
Methods: Residents (age  45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography, and phlebotomy for 2 novel assays specific for proBNP3-108 and BNP3-32 and 2 commercial assays (Triage BNP and Roche NT-proBNP). Groups included normal subjects (n = 613), cardiovascular disease with normal ventricular function (n = 1,043), preclinical ventricular dysfunction (ALVD, n = 130), and chronic heart failure (HF, n = 52).
Results: ProBNP3-108 levels were above assay detection limits in 68% of normal subjects (50th; 25th to 75th percentiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with results of commercial assays. ProBNP3-108 levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF (42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP3-32 was above assay detection limits in 22% of normal subjects; levels were not correlated with age, body size, or renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detection of ALVD or HF.
Conclusions: The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP processing in the general population. The physiologic consequences of these observations, both in terms of assay performance and endogenous BNP bioactivity, deserve further study.
|
Abbreviations and Acronyms
| | aa = amino acid | | ALVD = asymptomatic left ventricular dysfunction | | BNP = B-type natriuretic peptide | | BSA = body surface area | | CV = cardiovascular | | EF = ejection fraction | | GFR = glomerular filtration rate | | HF = heart failure | | MDC = minimal detectable concentration | | NT = N-terminal | | ROC = receiver operating characteristic |
|
This article has been cited by other articles:
|
|
|
|
 
A. M. Jansson, H. Rosjo, T. Omland, T. Karlsson, M. Hartford, A. Flyvbjerg, and K. Caidahl
Prognostic value of circulating chromogranin A levels in acute coronary syndromes
Eur. Heart J.,
January 1, 2009;
30(1):
25 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Miller, K. A. Hartman, D. E. Grill, J. C. Burnett Jr, and A. S. Jaffe
Only Large Reductions in Concentrations of Natriuretic Peptides (BNP and NT-proBNP) Are Associated with Improved Outcome in Ambulatory Patients with Chronic Heart Failure
Clin. Chem.,
January 1, 2009;
55(1):
78 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Frankenstein, A. Remppis, M. Nelles, B. Schaelling, D. Schellberg, H. Katus, and C. Zugck
Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status
Eur. Heart J.,
November 1, 2008;
29(21):
2634 - 2640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E. Niederkofler, U. A. Kiernan, J. O'Rear, S. Menon, S. Saghir, A. A. Protter, R. W. Nelson, and U. Schellenberger
Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart Failure
Circ Heart Fail,
November 1, 2008;
1(4):
258 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux
Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department
QJM,
November 1, 2008;
101(11):
831 - 843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Goetze, U. Dahlstrom, J. F. Rehfeld, and U. Alehagen
Impact of Epitope Specificity and Precursor Maturation in Pro-B-Type Natriuretic Peptide Measurement
Clin. Chem.,
November 1, 2008;
54(11):
1780 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Waldo, J. Beede, S. Isakson, S. Villard-Saussine, J. Fareh, P. Clopton, R. L. Fitzgerald, and A. S. Maisel
Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1874 - 1882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Seferian, N. N. Tamm, A. G. Semenov, A. A. Tolstaya, E. V. Koshkina, M. I. Krasnoselsky, A. B. Postnikov, D. V. Serebryanaya, F. S. Apple, M. M. Murakami, et al.
Immunodetection of Glycosylated NT-proBNP Circulating in Human Blood
Clin. Chem.,
May 1, 2008;
54(5):
866 - 873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2357 - 2368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
December 11, 2007;
50(24):
2344 - 2351.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nybo, M. Benn, R. Mogelvang, J. S. Jensen, P. Schnohr, J. F. Rehfeld, and J. P. Goetze
Impact of Hemoglobin on Plasma Pro-B-Type Natriuretic Peptide Concentrations in the General Population
Clin. Chem.,
November 1, 2007;
53(11):
1921 - 1927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
